Ipsen's Dysport Becomes First Botulinum Toxin To Show Statistically Significant Efficacy In Episodic Migraine, Positioning It As Potential First-In-Class Treatment
Dysport achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine
Dysport is the first botulinum toxin in episodic migraine to demonstrate a statistically significant reduction in monthly migraine days
Dysport was well-tolerated across both trials with safety consistent with the known profile
Login to comment